Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Anika Therapeutics (NQ: ANIK )

27.37 +0.49 (+1.82%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 36,852
Open 26.72
Bid (Size) 25.83 (1)
Ask (Size) 28.34 (1)
Prev. Close 26.88
Today's Range 26.68 - 27.49
52wk Range 20.12 - 32.51
Shares Outstanding 14,757,151
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Recap: Anika Therapeutics Q1 Earnings
 
Via Benzinga
Anika to Issue First Quarter 2023 Financial Results on Tuesday, May 9, 2023
From Anika Therapeutics Inc.
Via GlobeNewswire

Performance

YTD
-7.16%
-7.16%
1 Month
+6.09%
+6.09%
3 Month
-12.75%
-12.75%
6 Month
-6.81%
-6.81%
1 Year
+24.13%
+24.13%

More News

Read More
Anika Enters Into Cooperation Agreement with Caligan Partners
From Anika Therapeutics Inc.
Via GlobeNewswire
Anika to Participate in the 22nd Annual Needham Virtual Healthcare Conference
From Anika Therapeutics Inc.
Via GlobeNewswire
Anika Therapeutics Earnings Preview
Via Benzinga
New FDA 510(k) Clearance Expands Anika's Sports Medicine Soft Tissue Portfolio
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Anika Continues to Expand Addressable Market for Tactoset® Injectable Bone Substitute with Additional 510(k) Clearance from FDA
From Anika Therapeutics Inc.
Via GlobeNewswire
Anika Files Preliminary Proxy Statement
From Anika Therapeutics Inc.
Via GlobeNewswire
Anika to Participate in the Sidoti Small Cap Virtual Investor Conference
From Anika Therapeutics Inc.
Via GlobeNewswire
Anika Highlights Products in High Growth Segments of Joint Preservation during the 2023 AAOS Annual Meeting
From Anika Therapeutics Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2023
Via Benzinga
Anika to Participate in the Canaccord Genuity Musculoskeletal Conference
From Anika Therapeutics Inc.
Via GlobeNewswire
Anika to Issue Fourth Quarter and Year-End 2022 Financial Results on Monday, March 6, 2023
From Anika Therapeutics Inc.
Via GlobeNewswire
Anika Issues Statement
From Anika Therapeutics Inc.
Via GlobeNewswire
Anika Announces First Surgeries Performed Using the New RevoMotion™ Reverse Shoulder Arthroplasty System and Commences Limited Market Release in the United States
From Anika Therapeutics Inc.
Via GlobeNewswire
7 Stocks to Buy Before the Market Starts to Soar in 2023
Via InvestorPlace
Anika Therapeutics Cingal Tops Steroid For Osteoarthritis Pain Relief
Via Benzinga
Anika’s Cingal® Successfully Achieves Primary Endpoint in Third Phase III Study
From Anika Therapeutics Inc.
Via GlobeNewswire
Anika to Issue Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
From Anika Therapeutics Inc.
Via GlobeNewswire
Anika Therapeutics: Q2 Earnings Insights
Via Benzinga
Anika Receives the ACE Award for Cutting-Edge Innovation for Tactoset® Injectable Bone Substitute from the American Orthopedic Society for Sports Medicine
From Anika Therapeutics Inc.
Via GlobeNewswire
Sidoti's Summer Small Cap Virtual Conference
From Sidoti & Company, LLC
Via AccessWire
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Anika Therapeutics: Q4 Earnings Insights
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.